SecBot SecBot
8-K ·Filed Aug 19, 2026

PDSB

PDS Biotechnology Corp
NEUTRAL
Impact 3/10
Horizonweeks Processed2mo ago SEC0001140361-26-033749
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for the permanent CFO appointment and any potential impact on financial reporting cadence, but this filing alone is routine for a micro-cap biotech. No immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.2089
T+0 close · Aug 19, 2026 · via day close
Latest settled
+317.71%
T+60 · $0.8726
Vs SPY
+318.79%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 20 $0.2089entry
  2. T+1 · 3mo ago +4.60%α +4.19% · $0.2185
  3. T+5 · 3mo ago +4.31%α +3.19% · $0.2179
  4. T+20 · 2mo ago +285.59%α +285.59% · $0.8055
  5. T+60 · 4d ago +317.71%α +318.79% · $0.8726
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PDS Biotechnology Corp disclosed the resignation of CFO Lars Boesgaard, effective September 12, 2026, to pursue other professional endeavors, with no disagreement cited. The company appointed Controller Janetta Trochimiuk as interim Principal Accounting Officer and CEO Frank Bedu-Addo as interim Principal Financial Officer, effective the same date. This is a routine CFO departure with internal replacements named, carrying no material financial impact for a $12M market cap biotech.

Key Facts

  • CFO Lars Boesgaard resigned effective September 12, 2026, to pursue other professional endeavors.
  • Resignation is not due to any disagreement with company operations, policies, or practices.
  • Janetta Trochimiuk, Controller, appointed interim Principal Accounting Officer effective September 12, 2026.
  • CEO Frank Bedu-Addo appointed interim Principal Financial Officer effective September 12, 2026.
  • Trochimiuk will continue at $279,519.57 annual base salary with no equity awards in connection with promotion.

Financial Impact

No material financial impact; CFO departure with internal replacements at disclosed salary of $279,519.57/year

Risk Factors

  • Extended CFO vacancy could strain financial reporting if interim arrangement persists
  • No permanent CFO search timeline disclosed

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-033749
Document: 0001140361-26-033749-index-headers.html0001140361-26-033749
Document: 0001140361-26-033749-index.html0001140361-26-033749
Document: 0001140361-26-033749.txt0001140361-26-033749

Track record

28 reports on PDSB

Performance horizon

7 of 14 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 14 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
  2. Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
  3. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
  4. Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  5. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  6. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
  7. Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
  8. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
  9. Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
  10. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 19, 2026